Adapting Summer Education Programs for Navajo Students: Resilient Teamwork

Autor: Carmella B. Kahn, Heather Dreifuss, Nicolette I. Teufel-Shone, Marissa Tutt, Kelly McCue, Jamie Wilson, Amber-Rose Waters, Kalvina L. Belin, Mark C. Bauer

Publikováno v: Frontiers in Sociology, Vol 6 (2021)

In May 2020, the Navajo Native American Research Center for Health Partnership (Navajo NARCH) was scheduled to launch two summer programs: a 10 weeks-long Summer Research Enhancement Program (SREP) for undergraduate students to learn and practice hea

Externí odkaz: https://doaj.org/article/a1ad3b0f639e4271be23cf7688a9042b

Cyclooxygenase‐2 polymorphisms in Parkinson's diseasePlease cite this article as follows: Håkansson A, Bergman O, Chrapkowska C, Westberg L, Belin AC, Sydow O, Johnels B, Olson L, Holmberg B, Nissbrandt H. 2007. Cyclooxygenase‐2 Polymorphisms in Parkinson's Disease. Am J Med Genet Part B 144B:367–369.

Autor: Håkansson, Anna, Bergman, Olle, Chrapkowska, Cecilia, Westberg, Lars, Belin, Andrea Carmine, Sydow, Olof, Johnels, Bo, Olson, Lars, Holmberg, Björn, Nissbrandt, Hans

Publikováno v: American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics; April 2007, Vol. 144 Issue: 3 p367-369, 3p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

P10.17.B Androgen receptor signalling has independent prognostic value and is associated with resistance to temozolomide and tumour growth in glioblastoma

Autor: C Birzu, J Boussier, L Belin, T Da Costa Pereira, E Quissac, M Zerara, N Lemaire, K Mokhtari, M Verreault, A Idbaih

Publikováno v: Neuro-Oncology. 24:ii52-ii53

Background The spectrum of sex differences in glioblastoma (GBM) is a rising topic. GBM is more frequent (sex ratio M:F=1.6) and seem to have worse prognosis in males (M) compared to females. Androgen receptor (AR) is expressed in GBM but its role in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::41c3e32038f0160fb70876ab1edf16ea
https://doi.org/10.1093/neuonc/noac174.182

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

Autor: J.E. Kurtz, E. Pujade-Lauraine, A. Oaknin, L. Belin, I. Tsibulak, D. Cibula, I.B. Vergote, O.S. Rosengarten, M.J. Rodrigues, N. de Gregorio, J. Martinez-Garcia, P. Pautier, M.A. Mouret Reynier, F. Selle, V. D'Hondt, F. Joly Lobbedez, E. Bultot Boissier, A. Floquet, P-E. Heudel, F. Heitz

Publikováno v: Annals of Oncology. 33:S1397

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8fda6ebcd7b031fa8144e1bb0b059ca3
https://doi.org/10.1016/j.annonc.2022.08.026